Latest Pharma Insights
Enhertu Scores In NSCLC, Advancing AstraZeneca’s And Daiichi’s Growth Strategies
The HER2-targeting ADC beat out Merck’s Keytruda combined with chemotherapy in frontline HER2-mutant non-small cell lung cancer.
Scrip - August 17, 2026
The HER2-targeting ADC beat out Merck’s Keytruda combined with chemotherapy in frontline HER2-mutant non-small cell lung cancer.
Scrip - August 17, 2026
Argenx’s Vyvgart Poised For First Rheumatology Expansion With Myositis Data
A successful Phase III study testing the FcRn inhibitor in immune-mediated necrotizing myopathy and dermatomyositis could represent two blockbuster-sized expansion opportunities.
Scrip - August 17, 2026
A successful Phase III study testing the FcRn inhibitor in immune-mediated necrotizing myopathy and dermatomyositis could represent two blockbuster-sized expansion opportunities.
Scrip - August 17, 2026
Mira Fertility Monitor’s Ad Claims Of Superiority Withdrawn On Clearblue Marketer P&G’s Challenge
National Advertising Division says Quanovate Tech withdrew numerous express claims for its Mira Fertility Monitor and Test Wands during review prompted by P&G challenge.
HBW Insight - August 17, 2026
National Advertising Division says Quanovate Tech withdrew numerous express claims for its Mira Fertility Monitor and Test Wands during review prompted by P&G challenge.
HBW Insight - August 17, 2026
Roche’s Barbara Lueckel On The Long Game In Research Technology Partnering
The global head of research technologies at Roche Pharma Partnering says novel modalities take time, trust matters as much as science, and compute power is the new currency of drug discovery.
In Vivo - August 17, 2026
The global head of research technologies at Roche Pharma Partnering says novel modalities take time, trust matters as much as science, and compute power is the new currency of drug discovery.
In Vivo - August 17, 2026
FDA Consumer Health Advisory: Supplements Facing High Compliance Costs, Reprieve On Hemp THC Limits
A quick read on the latest FDA consumer health news: what's happening, why it matters and what's next. This edition unpacks a costly GRAS shake-up for supplements, a slight reprieve from tighter hemp regulation, and mounting unpaid OTC fees.
HBW Insight - August 17, 2026
A quick read on the latest FDA consumer health news: what's happening, why it matters and what's next. This edition unpacks a costly GRAS shake-up for supplements, a slight reprieve from tighter hemp regulation, and mounting unpaid OTC fees.
HBW Insight - August 17, 2026
What The EU Packaging And Packaging Waste Regulation Means For Consumer Health Companies
The EU's Packaging and Packaging Waste Regulation now applies, bringing conformity documentation, substance limits, extended producer responsibility and recyclability obligations into force, with no exemptions for food supplements.
HBW Insight - August 17, 2026
The EU's Packaging and Packaging Waste Regulation now applies, bringing conformity documentation, substance limits, extended producer responsibility and recyclability obligations into force, with no exemptions for food supplements.
HBW Insight - August 17, 2026
AstraZeneca’s Challenge To Keytruda Falters As Volrustomig Lung Trial Halted
The decision puts the spotlight on the bispecific's remaining Phase III program across cervical cancer, head and neck cancer and mesothelioma.
Scrip - August 17, 2026
The decision puts the spotlight on the bispecific's remaining Phase III program across cervical cancer, head and neck cancer and mesothelioma.
Scrip - August 17, 2026
Medtronic Bets Its Surgical AI Future On Compute, Not Just The Hugo Robot
Medtronic has unveiled Touch Surgery Aide, an NVIDIA-based platform to run AI live during surgery, with a first FDA-cleared algorithm that flags when instruments leave a surgeon's view on its Hugo robot — a foundation its digital chief says will carry years of surgical AI.
Medtech Insight - August 17, 2026
Medtronic has unveiled Touch Surgery Aide, an NVIDIA-based platform to run AI live during surgery, with a first FDA-cleared algorithm that flags when instruments leave a surgeon's view on its Hugo robot — a foundation its digital chief says will carry years of surgical AI.
Medtech Insight - August 17, 2026
Silence Lays Out Phase III Plans For Divesiran In Polycythemia Vera
The biotech is eyeing a 2027 start for divesiran's Phase III trial as it plays catch-up to Takeda and Protagonist's rusfertide.
Scrip - August 17, 2026
The biotech is eyeing a 2027 start for divesiran's Phase III trial as it plays catch-up to Takeda and Protagonist's rusfertide.
Scrip - August 17, 2026
Pipeline Watch: Thirteen Approvals And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - August 17, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - August 17, 2026
How To Approach GLP-1 Approvals: Anvisa Leads By Example
Five GLP-1 approvals from Anvisa are set to extend treatment options for poorly controlled type 2 diabetes mellitus patients.
Generics Bulletin - August 17, 2026
Five GLP-1 approvals from Anvisa are set to extend treatment options for poorly controlled type 2 diabetes mellitus patients.
Generics Bulletin - August 17, 2026
Fresenius Kabi Pulls US Tocilizumab Lot As Recall Count Mounts
Fresenius Kabi has recalled a US lot of Tyenne over glass particles, extending a run of nationwide quality-related recalls that has also affected morphine and famotidine products.
Generics Bulletin - August 17, 2026
Fresenius Kabi has recalled a US lot of Tyenne over glass particles, extending a run of nationwide quality-related recalls that has also affected morphine and famotidine products.
Generics Bulletin - August 17, 2026
Meloxicam Price Spike Leads UK Increases In July
Meloxicam tablets in multiple strengths led the UK’s steepest generic price rises in July, according to the latest figures from WaveData.
Generics Bulletin - August 17, 2026
Meloxicam tablets in multiple strengths led the UK’s steepest generic price rises in July, according to the latest figures from WaveData.
Generics Bulletin - August 17, 2026
Ambient AI Blurs Regulatory Line Between Record And Medical Device
New MHRA guidance hopes to clarify whether ambient scribing tools count as medical devices – but global ambiguity remains.
Medtech Insight - August 17, 2026
New MHRA guidance hopes to clarify whether ambient scribing tools count as medical devices – but global ambiguity remains.
Medtech Insight - August 17, 2026
Sandoz Adds Scale And Subcutaneous Option In Major Henlius Biosimilars Deal
Sandoz has struck a major expanded deal with Henlius covering up to 10 biosimilars, potentially lifting its pipeline to 46 assets as it prepares for a broader wave of biologic loss-of-exclusivity opportunities.
Generics Bulletin - August 17, 2026
Sandoz has struck a major expanded deal with Henlius covering up to 10 biosimilars, potentially lifting its pipeline to 46 assets as it prepares for a broader wave of biologic loss-of-exclusivity opportunities.
Generics Bulletin - August 17, 2026
NVIDIA Wants To Become The Software Layer Supporting Surgical Robotics
The chipmaker is positioning itself not as a robot builder but as the foundational infrastructure for AI and robotics across medtech — from edge computing to open models and simulation. NVIDIA's David Niewolny tells Medtech Insight why the next race in surgical robotics will be won on software.
Medtech Insight - August 17, 2026
The chipmaker is positioning itself not as a robot builder but as the foundational infrastructure for AI and robotics across medtech — from edge computing to open models and simulation. NVIDIA's David Niewolny tells Medtech Insight why the next race in surgical robotics will be won on software.
Medtech Insight - August 17, 2026
Over The Counter: Building The GLP-1 Companion Category, With Beverley Law And Martina Gripp
ALL Creative founder Beverley Law and consultant Martina Gripp discuss what it takes to build a credible GLP-1 companion products category, from proving ingredients work in a specific need state to the claims grey area around naming a prescription drug.
HBW Insight - August 17, 2026
ALL Creative founder Beverley Law and consultant Martina Gripp discuss what it takes to build a credible GLP-1 companion products category, from proving ingredients work in a specific need state to the claims grey area around naming a prescription drug.
HBW Insight - August 17, 2026
AZ’s First China Deal Finally Pays Off With Phase III NSCLC Win
AstraZeneca in-licensed savolitinib, a MET inhibitor, from HUTCHMED in 2011. Fifteen years later, the molecule delivers its first win in a global late-stage trial in certain types of non-small cell lung cancer.
Scrip - August 17, 2026
AstraZeneca in-licensed savolitinib, a MET inhibitor, from HUTCHMED in 2011. Fifteen years later, the molecule delivers its first win in a global late-stage trial in certain types of non-small cell lung cancer.
Scrip - August 17, 2026
Executives On The Move: Six CEOs And Three CMOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at Korsana Biosciences, Ascentage Pharma and Neurvati Neurosciences, plus BioNTech gets a new CEO.
Scrip - August 17, 2026
Recent moves in the industry include C-suite changes at Korsana Biosciences, Ascentage Pharma and Neurvati Neurosciences, plus BioNTech gets a new CEO.
Scrip - August 17, 2026
Japan Q1 Roundup: Forex Tailwind Lifts International Sales
Major Japanese pharma firms report generally strong fiscal Q1 results, buoyed by the weaker yen and robust specialist portfolio performance, particularly in ADCs and neurology.
Scrip - August 17, 2026
Major Japanese pharma firms report generally strong fiscal Q1 results, buoyed by the weaker yen and robust specialist portfolio performance, particularly in ADCs and neurology.
Scrip - August 17, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: a look at the global IPF pipeline; US approval for Takeda's narcolepsy drug; Arrowhead talks differentiation in severe hypertriglyceridemia; SMID Q2 developments; and Attruby positioning in transthyretin-mediated amyloidosis with cardiomyopathy.
Scrip - August 17, 2026
In this week's episode: a look at the global IPF pipeline; US approval for Takeda's narcolepsy drug; Arrowhead talks differentiation in severe hypertriglyceridemia; SMID Q2 developments; and Attruby positioning in transthyretin-mediated amyloidosis with cardiomyopathy.
Scrip - August 17, 2026
Reese Consumer Health’s Transition To Developing, Marketing OTC Brands Has Australian Dream
Reese, which also markets PinWorm oral OTC and ColoTest blood test, acquires Australian Dream brand, for an undisclosed price, from Nature’s Health Connection in Campton, KY.
HBW Insight - August 17, 2026
Reese, which also markets PinWorm oral OTC and ColoTest blood test, acquires Australian Dream brand, for an undisclosed price, from Nature’s Health Connection in Campton, KY.
HBW Insight - August 17, 2026
Enhertu Scores In NSCLC, Advancing AstraZeneca’s And Daiichi’s Growth Strategies
The HER2-targeting ADC beat out Merck’s Keytruda combined with chemotherapy in frontline HER2-mutant non-small cell lung cancer.
Scrip - August 17, 2026
The HER2-targeting ADC beat out Merck’s Keytruda combined with chemotherapy in frontline HER2-mutant non-small cell lung cancer.
Scrip - August 17, 2026
Argenx’s Vyvgart Poised For First Rheumatology Expansion With Myositis Data
A successful Phase III study testing the FcRn inhibitor in immune-mediated necrotizing myopathy and dermatomyositis could represent two blockbuster-sized expansion opportunities.
Scrip - August 17, 2026
A successful Phase III study testing the FcRn inhibitor in immune-mediated necrotizing myopathy and dermatomyositis could represent two blockbuster-sized expansion opportunities.
Scrip - August 17, 2026
AstraZeneca’s Challenge To Keytruda Falters As Volrustomig Lung Trial Halted
The decision puts the spotlight on the bispecific's remaining Phase III program across cervical cancer, head and neck cancer and mesothelioma.
Scrip - August 17, 2026
The decision puts the spotlight on the bispecific's remaining Phase III program across cervical cancer, head and neck cancer and mesothelioma.
Scrip - August 17, 2026
Silence Lays Out Phase III Plans For Divesiran In Polycythemia Vera
The biotech is eyeing a 2027 start for divesiran's Phase III trial as it plays catch-up to Takeda and Protagonist's rusfertide.
Scrip - August 17, 2026
The biotech is eyeing a 2027 start for divesiran's Phase III trial as it plays catch-up to Takeda and Protagonist's rusfertide.
Scrip - August 17, 2026
Pipeline Watch: Thirteen Approvals And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - August 17, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - August 17, 2026
AZ’s First China Deal Finally Pays Off With Phase III NSCLC Win
AstraZeneca in-licensed savolitinib, a MET inhibitor, from HUTCHMED in 2011. Fifteen years later, the molecule delivers its first win in a global late-stage trial in certain types of non-small cell lung cancer.
Scrip - August 17, 2026
AstraZeneca in-licensed savolitinib, a MET inhibitor, from HUTCHMED in 2011. Fifteen years later, the molecule delivers its first win in a global late-stage trial in certain types of non-small cell lung cancer.
Scrip - August 17, 2026
Executives On The Move: Six CEOs And Three CMOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at Korsana Biosciences, Ascentage Pharma and Neurvati Neurosciences, plus BioNTech gets a new CEO.
Scrip - August 17, 2026
Recent moves in the industry include C-suite changes at Korsana Biosciences, Ascentage Pharma and Neurvati Neurosciences, plus BioNTech gets a new CEO.
Scrip - August 17, 2026
Japan Q1 Roundup: Forex Tailwind Lifts International Sales
Major Japanese pharma firms report generally strong fiscal Q1 results, buoyed by the weaker yen and robust specialist portfolio performance, particularly in ADCs and neurology.
Scrip - August 17, 2026
Major Japanese pharma firms report generally strong fiscal Q1 results, buoyed by the weaker yen and robust specialist portfolio performance, particularly in ADCs and neurology.
Scrip - August 17, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: a look at the global IPF pipeline; US approval for Takeda's narcolepsy drug; Arrowhead talks differentiation in severe hypertriglyceridemia; SMID Q2 developments; and Attruby positioning in transthyretin-mediated amyloidosis with cardiomyopathy.
Scrip - August 17, 2026
In this week's episode: a look at the global IPF pipeline; US approval for Takeda's narcolepsy drug; Arrowhead talks differentiation in severe hypertriglyceridemia; SMID Q2 developments; and Attruby positioning in transthyretin-mediated amyloidosis with cardiomyopathy.
Scrip - August 17, 2026
Medtronic Bets Its Surgical AI Future On Compute, Not Just The Hugo Robot
Medtronic has unveiled Touch Surgery Aide, an NVIDIA-based platform to run AI live during surgery, with a first FDA-cleared algorithm that flags when instruments leave a surgeon's view on its Hugo robot — a foundation its digital chief says will carry years of surgical AI.
Medtech Insight - August 17, 2026
Medtronic has unveiled Touch Surgery Aide, an NVIDIA-based platform to run AI live during surgery, with a first FDA-cleared algorithm that flags when instruments leave a surgeon's view on its Hugo robot — a foundation its digital chief says will carry years of surgical AI.
Medtech Insight - August 17, 2026
Ambient AI Blurs Regulatory Line Between Record And Medical Device
New MHRA guidance hopes to clarify whether ambient scribing tools count as medical devices – but global ambiguity remains.
Medtech Insight - August 17, 2026
New MHRA guidance hopes to clarify whether ambient scribing tools count as medical devices – but global ambiguity remains.
Medtech Insight - August 17, 2026
NVIDIA Wants To Become The Software Layer Supporting Surgical Robotics
The chipmaker is positioning itself not as a robot builder but as the foundational infrastructure for AI and robotics across medtech — from edge computing to open models and simulation. NVIDIA's David Niewolny tells Medtech Insight why the next race in surgical robotics will be won on software.
Medtech Insight - August 17, 2026
The chipmaker is positioning itself not as a robot builder but as the foundational infrastructure for AI and robotics across medtech — from edge computing to open models and simulation. NVIDIA's David Niewolny tells Medtech Insight why the next race in surgical robotics will be won on software.
Medtech Insight - August 17, 2026
Mira Fertility Monitor’s Ad Claims Of Superiority Withdrawn On Clearblue Marketer P&G’s Challenge
National Advertising Division says Quanovate Tech withdrew numerous express claims for its Mira Fertility Monitor and Test Wands during review prompted by P&G challenge.
HBW Insight - August 17, 2026
National Advertising Division says Quanovate Tech withdrew numerous express claims for its Mira Fertility Monitor and Test Wands during review prompted by P&G challenge.
HBW Insight - August 17, 2026
FDA Consumer Health Advisory: Supplements Facing High Compliance Costs, Reprieve On Hemp THC Limits
A quick read on the latest FDA consumer health news: what's happening, why it matters and what's next. This edition unpacks a costly GRAS shake-up for supplements, a slight reprieve from tighter hemp regulation, and mounting unpaid OTC fees.
HBW Insight - August 17, 2026
A quick read on the latest FDA consumer health news: what's happening, why it matters and what's next. This edition unpacks a costly GRAS shake-up for supplements, a slight reprieve from tighter hemp regulation, and mounting unpaid OTC fees.
HBW Insight - August 17, 2026
What The EU Packaging And Packaging Waste Regulation Means For Consumer Health Companies
The EU's Packaging and Packaging Waste Regulation now applies, bringing conformity documentation, substance limits, extended producer responsibility and recyclability obligations into force, with no exemptions for food supplements.
HBW Insight - August 17, 2026
The EU's Packaging and Packaging Waste Regulation now applies, bringing conformity documentation, substance limits, extended producer responsibility and recyclability obligations into force, with no exemptions for food supplements.
HBW Insight - August 17, 2026
Over The Counter: Building The GLP-1 Companion Category, With Beverley Law And Martina Gripp
ALL Creative founder Beverley Law and consultant Martina Gripp discuss what it takes to build a credible GLP-1 companion products category, from proving ingredients work in a specific need state to the claims grey area around naming a prescription drug.
HBW Insight - August 17, 2026
ALL Creative founder Beverley Law and consultant Martina Gripp discuss what it takes to build a credible GLP-1 companion products category, from proving ingredients work in a specific need state to the claims grey area around naming a prescription drug.
HBW Insight - August 17, 2026
Reese Consumer Health’s Transition To Developing, Marketing OTC Brands Has Australian Dream
Reese, which also markets PinWorm oral OTC and ColoTest blood test, acquires Australian Dream brand, for an undisclosed price, from Nature’s Health Connection in Campton, KY.
HBW Insight - August 17, 2026
Reese, which also markets PinWorm oral OTC and ColoTest blood test, acquires Australian Dream brand, for an undisclosed price, from Nature’s Health Connection in Campton, KY.
HBW Insight - August 17, 2026
How To Approach GLP-1 Approvals: Anvisa Leads By Example
Five GLP-1 approvals from Anvisa are set to extend treatment options for poorly controlled type 2 diabetes mellitus patients.
Generics Bulletin - August 17, 2026
Five GLP-1 approvals from Anvisa are set to extend treatment options for poorly controlled type 2 diabetes mellitus patients.
Generics Bulletin - August 17, 2026
Fresenius Kabi Pulls US Tocilizumab Lot As Recall Count Mounts
Fresenius Kabi has recalled a US lot of Tyenne over glass particles, extending a run of nationwide quality-related recalls that has also affected morphine and famotidine products.
Generics Bulletin - August 17, 2026
Fresenius Kabi has recalled a US lot of Tyenne over glass particles, extending a run of nationwide quality-related recalls that has also affected morphine and famotidine products.
Generics Bulletin - August 17, 2026
Meloxicam Price Spike Leads UK Increases In July
Meloxicam tablets in multiple strengths led the UK’s steepest generic price rises in July, according to the latest figures from WaveData.
Generics Bulletin - August 17, 2026
Meloxicam tablets in multiple strengths led the UK’s steepest generic price rises in July, according to the latest figures from WaveData.
Generics Bulletin - August 17, 2026
Sandoz Adds Scale And Subcutaneous Option In Major Henlius Biosimilars Deal
Sandoz has struck a major expanded deal with Henlius covering up to 10 biosimilars, potentially lifting its pipeline to 46 assets as it prepares for a broader wave of biologic loss-of-exclusivity opportunities.
Generics Bulletin - August 17, 2026
Sandoz has struck a major expanded deal with Henlius covering up to 10 biosimilars, potentially lifting its pipeline to 46 assets as it prepares for a broader wave of biologic loss-of-exclusivity opportunities.
Generics Bulletin - August 17, 2026
Roche’s Barbara Lueckel On The Long Game In Research Technology Partnering
The global head of research technologies at Roche Pharma Partnering says novel modalities take time, trust matters as much as science, and compute power is the new currency of drug discovery.
In Vivo - August 17, 2026
The global head of research technologies at Roche Pharma Partnering says novel modalities take time, trust matters as much as science, and compute power is the new currency of drug discovery.
In Vivo - August 17, 2026